Small cell lung cancer (SCLC) is a fast-growing cancer that can spread to other parts of the body like the brain and liver. This study is testing a new drug called *ABBV-706* compared to usual treatments like *topotecan*, *lurbinectedin*, or *amrubicin*. *ABBV-706* is given through an IV (a needle in your vein).
In total, around 531 adults will join this study at 175 locations worldwide. The study will last about 53 months, or nearly 4.5 years. Participants will have to visit the hospital or clinic regularly and undergo tests and scans to see how the treatment is working.
- Study will last about 4.5 years with regular hospital visits.
- Participants might face more tests and check-ups than usual treatment.
- Participants will receive either the new drug or usual treatment options.
How understandable was the trial content above?
Hard to understand
Easy to understand